VEIN STEP: A Prospective, Observational, International Study to Assess Effectiveness of Conservative Treatments in Chronic Venous Disease.
Chronic venous disease
Conservative therapy
Micronized purified flavonoid fraction
Observational
Quality of life
Venoactive drug
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
19
07
2023
accepted:
09
08
2023
medline:
27
11
2023
pubmed:
20
9
2023
entrez:
20
9
2023
Statut:
ppublish
Résumé
VEIN STEP was conducted to collect international data on the management of chronic venous disease (CVD) and to assess the effectiveness of conservative treatments for the relief of CVD signs and symptoms. This international, observational, prospective, longitudinal, cohort study recruited adult outpatients consulting for symptomatic CVD. The primary objective was the effectiveness of conservative treatments on symptoms, signs and quality of life in a real-life setting assessed using a range of patient-reported outcome measures: 10-cm Visual Analog and Patient Global Impression of Change scales for symptoms; Venous Clinical Severity Score for physician assessment of signs; and 14-item ChronIc Venous Insufficiency Questionnaire (CIVIQ-14) for quality of life. At inclusion, patients were prescribed conservative treatment according to the physicians' usual practice. Follow-up visits took place at weeks 2 and 4, with an optional week 8 visit. The analysis set comprised 6084 subjects (78% female) from nine countries with a mean age of 50.6 ± 13.8 years and BMI of 28.0 ± 4.9 kg/m In this prospective study conducted in the real-world setting, treatment with conservative therapy, in particular MPFF, was associated with meaningful improvements in the clinical signs and symptoms of disease as well as in quality of life in patients with CVD. ClinicalTrials.gov identifier NCT04574375. The VEIN STEP study aimed to gather global data on managing chronic venous disease (CVD) and evaluate the usefulness of conservative (non-surgical) treatments for improving CVD signs and symptoms. Persons included in the study group had symptomatic CVD and were visiting outpatient clinics. The main aim was to measure how well treatments improved symptoms, physical signs of the illness, and quality of life. Different methods were used to measure these aspects, such as rating symptoms on a 10-point scale and using questionnaires completed by patients and doctors. 6084 participants from nine countries joined the study. They were mostly women (78%) with an average age of around 50. Common symptoms included leg pain and leg heaviness. Treatments consisted mainly of drugs active on vein function, like MPFF and diosmin, along with compression stockings and creams. Conservative treatment led to symptom improvement in 89% of patients after 2 weeks and 96% at 4 weeks. Pain and leg heaviness improved in most patients (82% and 71% over the same period) while cramps, and swelling showed improvement in 45.5% and 46% of patients, respectively. Patients reported a significant decrease in symptom intensity, and doctors observed a reduction in disease severity. MPFF was associated with the highest reduction in symptom intensity. Improvements in quality of life were observed with all treatments but were greatest for MPFF. The study highlights that conservative treatments, especially MPFF, are associated with significant improvements in the clinical signs and symptoms of patients with CVD as well as in their quality of life.
Autres résumés
Type: plain-language-summary
(eng)
The VEIN STEP study aimed to gather global data on managing chronic venous disease (CVD) and evaluate the usefulness of conservative (non-surgical) treatments for improving CVD signs and symptoms.
Identifiants
pubmed: 37728696
doi: 10.1007/s12325-023-02643-6
pii: 10.1007/s12325-023-02643-6
pmc: PMC10567827
doi:
Banques de données
ClinicalTrials.gov
['NCT04574375']
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
5016-5036Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
Davies AH. The seriousness of chronic venous disease: a review of real-world evidence. Adv Ther. 2019;36(Suppl 1):5–12.
pubmed: 30758738
pmcid: 6824448
doi: 10.1007/s12325-019-0881-7
Vuylsteke ME, Colman R, Thomis S, Guillaume G, Van Quickenborne D. An epidemiological survey of venous disease among general practitioner attendees in different geographical regions on the globe: the final results of the Vein Consult Program. Angiology. 2018;69(9):779–85.
pubmed: 29482348
doi: 10.1177/0003319718759834
Ortega MA, Fraile-Martínez O, García-Montero C, Álvarez-Mon MA, Chaowen C, Ruiz-Grande F, et al. Understanding chronic venous disease: a critical overview of its pathophysiology and medical management. J Clin Med. 2021;10(15):3239.
pubmed: 34362022
pmcid: 8348673
doi: 10.3390/jcm10153239
Ono T, Bergan JJ, Schmid-Schönbein GW, Takase S. Monocyte infiltration into venous valves. J Vasc Surg. 1998;27(1):158–66.
pubmed: 9474094
doi: 10.1016/S0741-5214(98)70303-9
Takase S, Schmid-Schönbein G, Bergan JJ. Leukocyte activation in patients with venous insufficiency. J Vasc Surg. 1999;30(1):148–56.
pubmed: 10394165
doi: 10.1016/S0741-5214(99)70187-4
Bergan JJ, Pascarella L, Schmid-Schönbein GW. Pathogenesis of primary chronic venous disease: Insights from animal models of venous hypertension. J Vasc Surg. 2008;47(1):183–92.
pubmed: 18178472
doi: 10.1016/j.jvs.2007.09.028
Lurie F, Passman M, Meisner M, Dalsing M, Masuda E, Welch H, et al. The 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord. 2020;8(3):342–52.
pubmed: 32113854
doi: 10.1016/j.jvsv.2019.12.075
Benigni JP, Bihari I, Rabe E, Uhl JF, Partsch H, Cornu-Thenard A, Jawien A, UIP-Union Internationale de Phlébologie. Venous symptoms in C0 and C1 patients: UIP consensus document. Int Angiol. 2013;32(3):261–5.
pubmed: 23711678
Bogachev V, Arribas JMJ, Baila S, Ulloa Dominguez J, Walter J, Maharaj D, Marin A. Management and evaluation of treatment adherence and effectiveness in chronic venous disorders: results of the international study VEIN Act Program. Drugs & Therapy Perspec. 2019;35:396–404.
doi: 10.1007/s40267-019-00637-5
Lee AJ, Robertson LA, Boghossian SM, Allan PL, Ruckley CV, Fowkes FG, et al. Progression of varicose veins and chronic venous insufficiency in the general population in the Edinburgh Vein Study. J Vasc Surg Venous Lymphat Disord. 2015;3:18e26.
Carradice D, Mazari FA, Samuel N, Allgar V, Hatfield J, Chetter IC. Modelling the effect of venous disease on quality of life. Br J Surg. 2011;98(8):1089–98.
pubmed: 21604256
doi: 10.1002/bjs.7500
Branisteanu DE, Feodor T, Baila S, Mitea IA, Vittos O. Impact of chronic venous disease on quality of life: results of Vein Alarm study. Exp Ther Med. 2019;17(2):1091–6.
pubmed: 30679979
Santiago FR, Ulloa J, Régnier C, Peudon T, Braund E, Fradet-Aubignat C, Gianesini S. The impact of lower limb chronic venous disease on quality of life: patient and physician perspectives. J Comp Eff Res. 2022;11(11):789–803.
pubmed: 35642553
doi: 10.2217/cer-2022-0054
Kuet ML, Lane TR, Anwar MA, Davies AH. Comparison of disease-specific quality of life tools in patients with chronic venous disease. Phlebology. 2014;29(10):648–53.
pubmed: 23963729
doi: 10.1177/0268355513501302
Launois R. Health-related quality-of-life scales specific for chronic venous disorders of the lower limbs. J Vasc Surg Venous Lymphat Disord. 2015;3(2):219–27.
pubmed: 26993844
doi: 10.1016/j.jvsv.2014.08.005
Rabe E, Pannier F. Societal costs of chronic venous disease in CEAP C4, C5, C6 disease. Phlebology. 2010;25(Suppl 1):64–7.
pubmed: 20870821
doi: 10.1258/phleb.2010.010s09
Kim Y, Png CYM, Sumpio BJ, DeCarlo CS, Dua A. Defining the human and health care costs of chronic venous insufficiency. Semin Vasc Surg. 2021;34(1):59–64.
pubmed: 33757637
doi: 10.1053/j.semvascsurg.2021.02.007
De Maeseneer MG, Kakkos SK, Aherne T, et al. Editor’s Choice—European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg. 2022;63(2):184–267.
pubmed: 35027279
doi: 10.1016/j.ejvs.2021.12.024
Tazi Mezalek Z, Ulloa JH. VEIN STEP: Chronic venous disorders management and treatment effectiveness evaluation in chronic venous disease, an international observational prospective study. Results from Morocco. Phlebolymphology. 2021;28(2):68–71.
Launois R, Le Moine JG, Lozano FS, Mansilha A. Construction and international validation of CIVIQ-14 (a short form of CIVIQ-20), a new questionnaire with a stable factorial structure. Qual Life Res. 2012;21(6):1051–8.
pubmed: 21947689
doi: 10.1007/s11136-011-0008-3
Radak DJ, Vlajinac HD, Marinković JM, Maksimović MŽ, Maksimović ZV. Quality of life in chronic venous disease patients measured by short Chronic Venous Disease Quality of Life Questionnaire (CIVIQ-14) in Serbia. J Vasc Surg. 2013;58(4):1006–13.
pubmed: 22051876
doi: 10.1016/j.jvs.2011.08.003
Le Moine JG, Fiestas-Navarrete L, Katumba K, Launois R. Psychometric validation of the 14 items ChronIc Venous Insufficiency Quality of Life Questionnaire (CIVIQ-14): confirmatory factor analysis. Eur J Vasc Endovasc Surg. 2016;51(2):268–74.
pubmed: 26520178
doi: 10.1016/j.ejvs.2015.08.020
Rutherford RB, Padberg FT Jr, Comerota AJ, Kistner RL, Meissner MH, Moneta GL. Venous severity scoring: an adjunct to venous outcome assessment. J Vasc Surg. 2000;31(6):1307–12.
pubmed: 10842165
doi: 10.1067/mva.2000.107094
Vasquez MA, Rabe E, McLafferty RB, Shortell CK, Marston WA, Gillespie D, American Venous Forum Ad Hoc Outcomes Working Group, et al. Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American Venous Forum Ad Hoc Outcomes Working Group. J Vasc Surg. 2010;52(5):1387–96.
pubmed: 20875713
doi: 10.1016/j.jvs.2010.06.161
Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F, VCP Coordinators. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105–15.
pubmed: 22466974
Kavousi Y, Al Adas Z, Karamanos E, Kennedy N, Kabbani LS, Lin JC. Men present with higher clinical class of chronic venous disease before endovenous catheter ablation. J Vasc Surg Venous Lymphat Disord. 2018;6(6):702–6.
pubmed: 30064962
doi: 10.1016/j.jvsv.2018.05.024
Orhurhu V, Chu R, Xie K, Kamanyi GN, Salisu B, Salisu-Orhurhu M, Urits I, Kaye RJ, Hasoon J, Viswanath O, Kaye AJ, Karri J, Marshall Z, Kaye AD, Anahita D. Management of lower extremity pain from chronic venous insufficiency: a comprehensive review. Cardiol Ther. 2021;10(1):111–40.
pubmed: 33704678
pmcid: 8126535
doi: 10.1007/s40119-021-00213-x
Raju S, Hollis K, Neglen P. Use of compression stockings in chronic venous disease: patient compliance and efficacy. Ann Vasc Surg. 2007;21(6):790–5.
pubmed: 17980798
doi: 10.1016/j.avsg.2007.07.014
Moffatt CJ, Franks PJ, Doherty DC, Smithdale R, Steptoe A. Psychological factors in leg ulceration: a case-control study. Br J Dermatol. 2009;161(4):750–6.
pubmed: 19523173
doi: 10.1111/j.1365-2133.2009.09211.x
Finlayson K, Edwards H, Courtney M. The impact of psychosocial factors on adherence to compression therapy to prevent recurrence of venous leg ulcers. J Clin Nurs. 2010;19(9–10):1289–97.
pubmed: 20500338
doi: 10.1111/j.1365-2702.2009.03151.x
Cazaubon M, Benigni JP, Steinbruch M, Jabbour V, Gouhier-Kodas C. Is there a difference in the clinical efficacy of diosmin and micronized purified flavonoid fraction for the treatment of chronic venous disorders? Review of available evidence. Vasc Health Risk Manag. 2021;17:591–600.
pubmed: 34556990
pmcid: 8455100
doi: 10.2147/VHRM.S324112
Cospite M, Dominici A. Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form. Int Angiol. 1989;8(4 Suppl):61–5.
pubmed: 2698903
Paysant J, Sansilvestri-Morel P, Bouskela E, Verbeuren TJ. Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its anti-hyperpermeability effect in the hamster cheek pouch microcirculation. Int Angiol. 2008;27(1):81–5.
pubmed: 18277344
das Graças C, de Souza M, Cyrino FZ, de Carvalho JJ, Blanc-Guillemaud V, Bouskela E. Protective effects of micronized purified flavonoid fraction (MPFF) on a novel experimental model of chronic venous hypertension. Eur J Vasc Endovasc Surg. 2018;55(5):694–702.
doi: 10.1016/j.ejvs.2018.02.009
Bogachev V, Boldin B, Turkin P, Samenkov A, Dzhenina O. Micronized purified flavonoid fraction-based conservative treatment of chronic venous disease in a real-world setting. Future Cardiol. 2022;18(10):777–85.
pubmed: 36004765
doi: 10.2217/fca-2022-0026
Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol. 2018;37(2):143–54.
pubmed: 29385792
doi: 10.23736/S0392-9590.18.03975-5
Mansilha A, Gianesini S, Ulloa JH, Lobastov K, Wang J, Freitag A, Schaible KR, Martin M, Yaltirik P, Nicolaides AN. Pharmacological treatment for chronic venous disease: an umbrella review of systematic reviews. Int Angiol. 2022;41(3):249–57.
pubmed: 35373942
doi: 10.23736/S0392-9590.22.04877-5
Nicolaides AN, Allegra C, Bergan J, Bradbury A, Cairols M, Carpentier P, et al. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Int Angiol. 2008;27(1):1–59.
pubmed: 18277340
doi: 10.1177/000331970005100101
Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, Gillespie DL, Gloviczki ML, Society for Vascular Surgery; American Venous Forum, et al. American Venous Forum The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011;53(5 Suppl):2S-48S.
pubmed: 21536172
doi: 10.1016/j.jvs.2011.01.079
Wittens C, Davies AH, Bækgaard N, Broholm R, Cavezzi A, Chastanet S, et al. Editor’s choice—management of chronic venous disease: clinical practice guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2015;49(6):678–737.
pubmed: 25920631
doi: 10.1016/j.ejvs.2015.02.007
Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B, et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Part I. Int Angiol. 2018;37(3):181–254.
pubmed: 29871479
doi: 10.23736/S0392-9590.18.03999-8